Alpha Cognition Inc. (ACOGF)

Overview

Alpha Cognition Inc. embodies a clinical stage biopharmaceutical entity concentrated on pioneering treatments for critical neurological disorders, prominently Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Established in the year 2000 and initially known as Crystal Bridge Enterprises Inc., the company rebranded itself to Alpha Cognition Inc. in March 2021. The headquarters of Alpha Cognition Inc. are strategically placed in Vancouver, Canada, reflecting its commitment towards addressing global neurological challenges through innovative biomedical solutions.

Products and Services

Alpha Cognition Inc.'s product pipeline is a testament to its dedication to combating neurodegenerative diseases through a mix of groundbreaking and traditional approaches, including:

• ALPHA-1062: This is an acetylcholine esterase inhibitor designed primarily for the treatment of dementia of the Alzheimer's type. It also holds potential for addressing mild traumatic brain injury. ALPHA-1062 is indicative of Alpha Cognition's commitment towards improving the quality of life for patients suffering from Alzheimer's disease by reducing the progression of symptoms.
• ALPHA-0602: Alpha Cognition is venturing into gene therapy with ALPHA-0602, targeted at treating ALS. Recognizing the urgent need for effective treatments for ALS, ALPHA-0602 represents a cutting-edge approach to potentially halt or reverse the devastating effects of this condition.
• ALPHA-0702 and ALPHA-0802: Both of these are based on granulin epithelin motifs, focusing on the treatment of neurodegenerative diseases more broadly. These treatments are part of Alpha Cognition's research into innovative methods to fight against the degeneration of the nervous system caused by various diseases.